Insider Selling: Alphatec (NASDAQ:ATEC) Director Sells $636,000.00 in Stock

Alphatec Holdings, Inc. (NASDAQ:ATEC) Director David Demski sold 30,000 shares of the company’s stock in a transaction on Thursday, December 11th. The shares were sold at an average price of $21.20, for a total transaction of $636,000.00. Following the completion of the sale, the director directly owned 399,623 shares in the company, valued at approximately $8,472,007.60. The trade was a 6.98% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Alphatec Stock Performance

NASDAQ ATEC opened at $19.96 on Monday. The firm has a market capitalization of $2.97 billion, a P/E ratio of -19.19 and a beta of 1.08. The stock has a 50-day simple moving average of $18.42 and a two-hundred day simple moving average of $15.12. The company has a debt-to-equity ratio of 43.02, a quick ratio of 1.24 and a current ratio of 1.99. Alphatec Holdings, Inc. has a fifty-two week low of $8.69 and a fifty-two week high of $22.66.

Alphatec (NASDAQ:ATEC) last posted its earnings results on Thursday, October 30th. The medical technology company reported $0.03 EPS for the quarter, topping the consensus estimate of ($0.06) by $0.09. The company had revenue of $196.50 million for the quarter, compared to analyst estimates of $182.78 million. The firm’s revenue was up 30.4% on a year-over-year basis. During the same period last year, the business earned ($0.28) earnings per share. On average, equities analysts forecast that Alphatec Holdings, Inc. will post -1.08 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the stock. Needham & Company LLC lifted their target price on shares of Alphatec from $16.00 to $22.00 and gave the company a “buy” rating in a report on Friday, October 31st. Lake Street Capital set a $25.00 price objective on shares of Alphatec and gave the company a “buy” rating in a report on Friday, October 31st. Morgan Stanley set a $23.00 price objective on shares of Alphatec in a research report on Tuesday, December 2nd. Weiss Ratings restated a “sell (e+)” rating on shares of Alphatec in a research report on Monday, December 8th. Finally, Barclays upped their price target on Alphatec from $22.00 to $23.00 and gave the stock an “overweight” rating in a report on Monday, November 3rd. Nine equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Alphatec presently has a consensus rating of “Moderate Buy” and a consensus target price of $22.45.

Institutional Trading of Alphatec

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. raised its position in shares of Alphatec by 2.4% during the 3rd quarter. Vanguard Group Inc. now owns 6,815,058 shares of the medical technology company’s stock worth $99,091,000 after purchasing an additional 158,295 shares during the last quarter. American Century Companies Inc. increased its stake in Alphatec by 2.6% during the 3rd quarter. American Century Companies Inc. now owns 6,336,491 shares of the medical technology company’s stock worth $92,133,000 after buying an additional 159,330 shares in the last quarter. Royal Bank of Canada raised its holdings in shares of Alphatec by 10.8% during the first quarter. Royal Bank of Canada now owns 3,527,939 shares of the medical technology company’s stock valued at $35,773,000 after acquiring an additional 342,656 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of Alphatec by 7.4% during the second quarter. Geode Capital Management LLC now owns 2,697,541 shares of the medical technology company’s stock valued at $29,946,000 after acquiring an additional 185,297 shares during the last quarter. Finally, Next Century Growth Investors LLC lifted its position in shares of Alphatec by 22.8% in the second quarter. Next Century Growth Investors LLC now owns 2,060,735 shares of the medical technology company’s stock valued at $22,874,000 after acquiring an additional 382,057 shares in the last quarter. Hedge funds and other institutional investors own 66.35% of the company’s stock.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.